Reuters, Andrew Chung, Jun 12, 2017 The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9-0 […]
All posts by: Anke
NICE, UK, 30 May 2017 NICE is launching an online tool to help medtech companies get their products to patients faster. NICE’s Scientific Advice service is launching an online tool to help developers of medical devices and diagnostics understand and generate the evidence needed to show their products are clinically and cost effective. This will […]
FiercePharma, by Tracy Staton on May 3, 2017 Years ago, after a series of high-profile scandals, teaching hospitals around the country started raising hurdles to pharma reps. Some outright barred salespeople at the door. Others just required appointments. However they managed it, they apparently changed prescribing habits, too. That’s the conclusion of a new study, […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
by Evan Sweeney on Apr 14, 2017 in FierceHealthcare Healthcare providers and digital health companies are searching desperately for ways to get patients more engaged in their care. Doing so may require some radical changes to care delivery. As smartphones and mobile devices have become more ingrained in everyday life, many view technology as the […]
by Nick Paul Taylor |in FierceBiotech on Apr 19, 2017 The European Commission has again sought to extinguish the United Kingdom’s lingering hopes of keeping the European Medicines Agency (EMA) in London after Brexit. Lead Brexiteer David Davis became the latest politician to claim London could retain the regulator earlier this week, only for a […]
by Amirah Al Idrus in FierceBiotech on Apr 19, 2017 Verily’s Project Baseline, which aims to better understand what it means to be healthy and how health transitions to disease, has launched in partnership with Duke University and Stanford University. The study will collect health data from 10,000 participants over four years. The study will […]
by Nick Paul Taylor on Mar 30, 2017 in FierceBiotech Germany’s healthcare cost watchdog is continuing to push back against the European Medicines Agency’s (EMA) plans to accelerate the approval of new medicines. The German institute worries fast-track drug approvals based on limited clinical trial data or real-world evidence will become the norm—and that this […]
10. Aug. 2016, FiercePharma, Tracy Staton Copay discount programsbecome popular among biosimilar manufacturers to boost the adoption of their products. These copay assistence programs can come in form of upfront out-of-pocket financial support (e.g. Sun Pharmaceuticals for their Gleevec-alike imatinib mesylate) or the reduction of upfront cost to the patients (e.g. the cost of the […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]